Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Glioblastoma 2Recurrence 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Radiotherapy 38Carboplatin 37pembrolizumab 36Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Magnetic Resonance Spectroscopy 16Cyclophosphamide 15osimertinib 14Irinotecan 13Etoposide 13Radiation 12Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 8Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Crizotinib × Clear all
NCT02511184 2019-07-01

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Pfizer

Phase 1 Terminated
9 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Pfizer

Phase 1 Completed
27 enrolled 22 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡